

Certificate of Analysis for NR-48555

Enterobacter aerogenes, Strain UCI 15

Catalog No. NR-48555

Product Description: Enterobacter aerogenes (E. aerogenes), strain UCI 15 was isolated in 2013 from aspirate taken from a patient in intensive care in Irvine, California, USA. E. aerogenes, strain UCI 15 was deposited as a carbapenem resistant strain and is part of a Carbapenem Resistant Enterobacteriaeceae (CRE) Sequencing Project at the Broad Institute. Strain UCI 15 was also deposited as resistant to ampicillin, ampicillin/sulbactam, meropenem and cefoxitin and sensitive to amikacin.

Lot¹: 70005950 Manufacturing Date: 22JUN2017

| TEAT | ODEOJEJO A TJONIO | DECLU TO |
|--------------------------------------|--|--|
| TEST | SPECIFICATIONS | RESULTS |
| Phenotypic Analysis | | |
| Cellular morphology | Gram-negative rods | Gram-negative rods |
| Colony morphology ² | Report results | Circular, convex, entire, smooth, mucoid and gray (Figure 1) |
| Motility (wet mount) | Motile | Motile |
| VITEЌ [®] 2 (GN card) | ≥ 90% probability of being <i>E. aerogenes</i> | E. aerogenes (99% probability) ³ |
| Antibiotic Susceptibility Profile | | |
| VITEK® (AST-GN69 Card)4-6 | | |
| Amoxicillin/Clavulanic Acid | Resistant | Resistant (≥ 32 µg/mL) |
| Piperacillin/Tazobactam | Resistant | Resistant (≥ 128 µg/mL) |
| Cefazolin | Resistant | Resistant (≥ 64 µg/mL) |
| Ceftazidime | Resistant | Resistant (≥ 64 µg/mL) |
| Ceftriaxone | Resistant | Resistant (≥ 64 µg/mL) |
| Cefepime | Sensitive | Sensitive (2 µg/mL) ⁷ |
| Ertapenem | Resistant | Resistant (4 µg/mL) ⁸ |
| Imipenem | Intermediate | Sensitive (1 µg/mL) ⁹ |
| Gentamicin | Resistant | Resistant (≥ 16 µg/mL) |
| Tobramycin | Intermediate | Intermediate (8 µg/mL) |
| Ciprofloxacin | Sensitive | Sensitive (≤ 0.25 µg/mL) |
| Levofloxacin | Sensitive | Sensitive (≤ 0.12 μg/mL) |
| Nitrofurantoin | Resistant | Resistant (256 µg/mL) |
| Trimethoprim/Sulfamethoxazole | Resistant | Resistant (≥ 320 µg/mL) |
| Genotypic Analysis | | |
| Sequencing of 16S ribosomal RNA gene | ≥ 99% sequence identity to | 99.9% sequence identity to |
| (~ 760 base pairs) | E. aerogenes, strain UCI 15 | E. aerogenes, strain UCI 15 |
| | (GenBank: JCKZ01000009.1) | (GenBank: JCKZ01000009.1) |
| Purity (post-freeze) ¹⁰ | Consistent with expected colony | Consistent with expected colony |
| | morphology | morphology |
| Viability (post-freeze) ² | Growth | Growth |

¹Lot 70005950 of NR-48555 was produced by inoculation of BEI Resources NRS-48555 (Lot: 63445873) into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic soy agar with 5% defibrinated sheep blood kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

www.beiresources.org

BEI Resources E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²1 day at 37°C in an aerobic atmosphere on Tryptic soy agar with 5% defibrinated sheep blood

³Percent probabilities above 90% indicate a close match to the typical biochemical pattern for the given organism, with a percent probability of 99% being a perfect match between the test reaction pattern and the unique biochemical pattern of the given organism or organism group. For additional information, please refer to O'Hara, C. M. and J. M. Miller. "Evaluation of the VITEK 2 ID-GNB Assay for Identification of Members of the Family Enterobacteriaceae and Other Nonenteric Gram-Negative Bacilli and Comparison with the VITEK GNI+ Card." J. Clin. Microbiol. 41 (2003): 2096-2101. PubMed: 12734254.

⁴Specificantons are based on the results of antibiotic susceptibility testing for NR-48555 lot 63445872.

⁵Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S22 (2012)

⁶No results were obtained for ampicillin, ampicillin/sulbactam and Extended-Spectrum Beta-Lactamases (ESBLs) from the VITEK® (AST-GN69 Card) analysis. Alternative methods of testing are recommended by the manufacturer.




Certificate of Analysis for NR-48555

7E. aerogenes, strain UCI 15 was deposited as having intermediate susceptibility to cefepime. Because this isolate is not a confirmed ESBL-producer, the CLSI recommends utilization of the interpretation without subjugation to modifications based on the susceptibilities of other antibiotics in the same class. However, while this strain appears sensitive in vitro, there is a possibility that it is intermediately susceptible or resistant in vivo.

⁸E. aerogenes, strain UCI 15 was deposited as having intermediate susceptibility to ertapenem.

Figure 1: Colony Morphology



Date: 25 JUL 2017 Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

⁹E. aerogenes, strain UCI 15 was deposited as resistant to imipenem. Antibiotic susceptibility testing of NR-48555 lot 63445872 determined that strain UCI 15 was intermediately susceptible to imipenem.

¹⁰Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with 5% CO₂ on Tryptic soy agar with 5% defibrinated sheep blood.